Literature DB >> 12798652

Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response.

G Soboll1, K M Nelson, E S Leuthner, R J Clark, R Drape, M D Macklin, W F Swain, C W Olsen, D P Lunn.   

Abstract

We have previously demonstrated that equine influenza virus hemagglutinin (HA) DNA vaccination protects ponies from challenge infection, and induces protective IgGa and IgGb responses. However, this approach does not induce a nasal IgA response. The objective of this study was to examine the value of cholera toxin (CT) administration as an adjuvant for intranasal HA DNA vaccination, and to measure protection 3 months after DNA vaccination. After an immunogenic dose of CT was determined, ponies were immunized on two occasions by intranasal administration of HA DNA and cholera toxin, or HA DNA alone. Ponies in both groups received two additional HA DNA particle mediated vaccinations at skin and mucosal sites. Antibody responses, and protection from challenge infection 3 months after the last vaccination were studied and compared to an influenza virus naive control group. Ponies in both vaccination groups produced virus-specific IgG antibodies in serum following vaccination and showed clinical protection from challenge infection 3 months after the last vaccination. Co-administration of CT plus HA DNA vaccination induced a nasal IgA response. In addition, analysis of antibody titers in nasal secretions indicated local production of nasal IgGb, which was amplified by CT administration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798652     DOI: 10.1016/s0264-410x(03)00161-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies.

Authors:  Alida Ault; Alyse M Zajac; Wing-Pui Kong; J Patrick Gorres; Michael Royals; Chih-Jen Wei; Saran Bao; Zhi-yong Yang; Stephanie E Reedy; Tracy L Sturgill; Allen E Page; Jennifer Donofrio-Newman; Amanda A Adams; Udeni B R Balasuriya; David W Horohov; Thomas M Chambers; Gary J Nabel; Srinivas S Rao
Journal:  Vaccine       Date:  2012-03-23       Impact factor: 3.641

2.  Attenuation of equine influenza viruses through truncations of the NS1 protein.

Authors:  Michelle Quinlivan; Dmitriy Zamarin; Adolfo García-Sastre; Ann Cullinane; Thomas Chambers; Peter Palese
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route.

Authors:  R H Mealey; D M Stone; M T Hines; D C Alperin; M H Littke; S R Leib; S E Leach; S A Hines
Journal:  Vaccine       Date:  2007-08-15       Impact factor: 3.641

4.  Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses.

Authors:  T M Chambers; M Quinlivan; T Sturgill; A Cullinane; D W Horohov; D Zamarin; S Arkins; A García-Sastre; P Palese
Journal:  Equine Vet J       Date:  2009-01       Impact factor: 2.888

Review 5.  A Systematic Review of Recent Advances in Equine Influenza Vaccination.

Authors:  Romain Paillot
Journal:  Vaccines (Basel)       Date:  2014-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.